Results 21 to 30 of about 23,534 (120)

Long‐term safety and efficacy of the sodium–glucose cotransporter 2 inhibitor, tofogliflozin, added on glucagon‐like peptide‐1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52‐week open‐label, multicenter, post‐marketing clinical study

Journal of Diabetes Investigation, 2019
Aims/Introduction Tofogliflozin is a potent and highly selective sodium–glucose cotransporter 2 inhibitor that is currently used to treat patients with type 2 diabetes mellitus.
Yasuo Terauchi, Hisataka Fujiwara, Yuji Kurihara, Hideki Suganami, Masahiro Tamura, Masayuki Senda, Ryoji Gunji, Kohei Kaku   +7 more
doaj   +1 more source

The Novel Dual GLP-1/GIP Receptor Agonist DA-CH5 Is Superior to Single GLP-1 Receptor Agonists in the MPTP Model of Parkinson’s Disease

Journal of Parkinson’s Disease, 2020
Background: Parkinson’s disease (PD) is a progressive neurodegenerative disease for which there is no cure. In a clinical trial, the glucagon-like peptide-1 (GLP-1) receptor agonist exendin-4 has shown good protective effects in PD patients.
Lingyu Zhang, Liping Zhang, Yanwei Li, Lin Li, Josefine Ulrikke Melchiorsen, Mette Rosenkilde, Christian Hölscher   +6 more
doaj   +1 more source

Insulin–glucagon‐like peptide‐1 receptor agonist relay and glucagon‐like peptide‐1 receptor agonist first regimens in individuals with type 2 diabetes: A randomized, open‐label trial study

Journal of Diabetes Investigation, 2022
Aims/Introduction Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) might be less effective in patients with severe hyperglycemia, because hyperglycemia downregulated the GLP‐1 receptor in an animal study.
Yumie Takeshita, Yuki Kita, Takeo Tanaka, Hisanori Goto, Yujiro Nakano, Chisato Teramura, Yasufumi Enyama, Toshinari Takamura, the Establishment of Rationale for Antiaging Diabetic Medicine (ERA‐DM) Study Group   +8 more
doaj   +1 more source

In-Silico Design of Novel Glucagon-Like Peptide 1 Mutants as Candidate for New Peptide Agonist Drugs

Hayati Journal of Biosciences, 2021
The binding of glucagon-like peptide 1 (GLP-1) incretin hormone and its receptor GLP-1R plays an important role in the human body. The GLP-1 acts as the insulin secretion stimulator through a GLP-1R agonist activation to avoid the type 2 diabetes ...
Tony Sumaryada, Ajeng Widya Roslia, Alfi Afifah, Setyanto Tri Wahyudi, Agus Kartono   +4 more
doaj  

Spatiotemporal GLP-1 and GIP receptor signaling and trafficking/recycling dynamics induced by selected receptor mono- and dual-agonists

Molecular Metabolism, 2021
Objective: We assessed the spatiotemporal GLP-1 and GIP receptor signaling, trafficking, and recycling dynamics of GIPR mono-agonists, GLP-1R mono-agonists including semaglutide, and GLP-1/GIP dual-agonists MAR709 and tirzepatide.
Aaron Novikoff, Shannon L. O'Brien, Miriam Bernecker, Gerald Grandl, Maximilian Kleinert, Patrick J. Knerr, Kerstin Stemmer, Martin Klingenspor, Anja Zeigerer, Richard DiMarchi, Matthias H. Tschöp, Brian Finan, Davide Calebiro, Timo D. Müller   +13 more
doaj   +1 more source

Metabolic and gut microbiome changes following GLP-1 or dual GLP-1/GLP-2 receptor agonist treatment in diet-induced obese mice

Scientific Reports, 2019
Enteroendocrine L-cell derived peptide hormones, notably glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2), have become important targets in the treatment of type 2 diabetes, obesity and intestinal diseases.
Mette Simone Aae Madsen, Jacob Bak Holm, Albert Pallejà, Pernille Wismann, Katrine Fabricius, Kristoffer Rigbolt, Martin Mikkelsen, Morten Sommer, Jacob Jelsing, Henrik Bjørn Nielsen, Niels Vrang, Henrik H. Hansen   +11 more
doaj   +1 more source

Allosteric modulation of the activity of the glucagon-like peptide-1 (GLP-1) metabolite GLP-1 9-36 amide at the GLP-1 receptor. [PDF]

PLoS ONE, 2012
Glucagon-like peptide-1 (GLP-1) released from intestinal L cells in response to nutrients has many physiological effects but particularly enhances glucose-dependent insulin release through the GLP-1 receptor (GLP-1R).
Naichang Li, Jing Lu, Gary B Willars
doaj   +1 more source

Socioeconomic and Demographic Inequalities in Off-Label Prescription of Glucagon-Like Peptide-1 Receptor Agonists: A Swedish Descriptive Cohort Study

Obesity Facts
Introduction: In Sweden, glucagon-like peptide-1 (GLP-1) receptor agonists are subsidized for diabetes indication but not for obesity. Unregulated off-label prescription of GLP-1 receptor agonists for obesity treatment may raise concerns about
Laura Pazzagli, Ylva Trolle Lagerros
doaj   +1 more source

The GIP receptor displays higher basal activity than the GLP-1 receptor but does not recruit GRK2 or arrestin3 effectively.

PLoS ONE, 2014
Background and objectivesGlucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are important regulators of insulin secretion, and their functional loss is an early characteristic of type 2 diabetes mellitus (T2DM ...
Suleiman Al-Sabah, Munya Al-Fulaij, Ghina Shaaban, Hanadi A Ahmed, Rosalind J Mann, Dan Donnelly, Moritz Bünemann, Cornelius Krasel   +7 more
doaj   +1 more source

Comprehensively prognostic and immunological analyses of GLP-1 signaling-related genes in pan-cancer and validation in colorectal cancer

Frontiers in Pharmacology
Background: Glucagon-like peptide-1 (GLP-1) has crucial impact on glycemic control and weight loss physiologically. GLP-1 receptor agonists have been approved for treatment of diabetes and obesity.
Chaojun Zhu, Yihong Lai, Chengdong Liu, Lan Teng, Yuxin Zhu, Xinyu Lin, Xinyi Fu, Qiuhua Lai, Side Liu, Side Liu, Xiaohan Zhou, Yuxin Fang   +11 more
doaj   +1 more source